Trial Profile
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Pemafibrate (Primary)
- Indications Cardiovascular disorders; Hypertriglyceridaemia; Myocardial infarction; Stroke; Unstable angina pectoris
- Focus Registrational; Therapeutic Use
- Acronyms PROMINENT
- Sponsors Kowa
- 07 Nov 2022 Trial design, presented at the American Heart Association Scientific Sessions 2022
- 05 Nov 2022 Results published in the New England Journal of Medicine
- 08 Oct 2022 This trial has been completed in Slovakia (End date: 27 Jul 22), according to European Clinical Trials Registry record.